Arvanitakis et al. came to a similar conclusion in their review that by administering glucagon-like peptide 1 receptor agonists (GLP-1 RAs) to patients with IBD, the benefits of therapy can be maximized, among other things, by maintaining and adequately functioning TJ [108]. Here, GCG is linked to inflammatory bowel disease.